News Updates
Scope

Wed, May 27, 2026

1 updates
MTVA
8:31 AM

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels CAMBRIDGE,

Presentation / Abstract • Phase 1Late-breaking poster presentation Wed, May 27, 2026, 8:30 AM CETmetaviatx.com

Wed, May 20, 2026

1 updates

Mon, May 18, 2026

1 updates
MTVA
8:31 AM

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

Three Late-Breaking Posters Highlight DA-1726, a GLP-1 /Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that

Presentation / Abstract • Phase 1Late-breaking poster presentation Sun, Jun 7, 2026, 12:30 PM ETmetaviatx.com

Thu, May 14, 2026

1 updates
MTVA
4:05 PM

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step) and 64 mg (2-Step)

Presentation / Abstract • Phase 1EASL Congress 2026 poster presentation Thu, May 14, 2026metaviatx.com

Mon, May 11, 2026

1 updates

Fri, Apr 10, 2026

1 updates

Thu, Mar 26, 2026

1 updates

Wed, Mar 18, 2026

1 updates
MTVA
8:00 AM

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases,

metaviatx.com

Thu, Mar 12, 2026

1 updates

Wed, Mar 4, 2026

1 updates